Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,847
datasets available to search
ShareScore release 0.9.0
Dataset results
1,847 results for “Psoriasis”
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
ClinicalTrials.gov study NCT01090427. IPD Sharing: Not stated. Countries: 10. Publications: 2.
Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris
ClinicalTrials.gov study NCT01600222. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
ClinicalTrials.gov study NCT03835481. IPD Sharing: YES. Countries: 3. Publications: 2.
Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings
ClinicalTrials.gov study NCT00708708. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT01309737. IPD Sharing: Not stated. Countries: 11. Publications: 4.
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
ClinicalTrials.gov study NCT01365455. IPD Sharing: Not stated. Countries: 12. Publications: 9.
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
ClinicalTrials.gov study NCT01358578. IPD Sharing: Not stated. Countries: 23. Publications: 9.
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
ClinicalTrials.gov study NCT01553058. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Comorbidities in Psoriasis Among Iraqi Patients Attending al Yaemouk Teaching Hospital
<p><strong><u><span>ABSTRACT</span></u></strong>:</p> <p><strong>Background</strong>: Psoriasis is a chronic dermatological condition that has been shown to exhibit a correlation with a heightened prevalence of comorbidities, such as the metabolic syndrome. It is recommended that individuals diagnosed with psoriasis have regular screening for metabolic syndrome. <strong>Aim of study</strong>: Is to evaluate the rate of metabolic syndrome and depression in patients with psoriasis in comparison with control patients and to assess association of metabolic syndrome and depression with the severity of psoriasis. <strong>Methods</strong>: This is a case control study conducted in department of dermatology and venereology out-patient in Al Yarmouk teaching hospital, Baghdad, Iraq from January 2022 to January 2023. This study involved 100 psoriatic patients (cases) and 100 patients attended outpatient for other dermatological diseases (controls) and matched for same age and gender, two different questionnaires were used for all study. All patients were subjected to detailed History, complete physical examination, work-up for psoriasis disease diagnosis and further follow-up and management, and evaluation of metabolic syndrome and depression which was achieved by different tools mentioned<span> </span>previously. <strong>Results</strong>: 31% of them were overweighed while other 31% had normal BMI, 72% were normotensive and 78% were not depressed. 58% of psoriatic patients were presented as severe pattern. Psoriasis was significantly seen among obese patients (74.5%, P=0.001), depressed patients (72.7%, P=0.001). Also, it was significantly found in patients with high FBS (71%, P=0.011), hi cholesterol level (69.6%, P=0.02), hi TG (78.6, P=0.026), high<span> </span>LDL<span> </span>(69.2%,<span> </span>P=0.035),<span> </span>and<span> </span>low<span> </span>HDL<span> </span>(72.3%,<span> </span>P=0.001).<span> </span>Severe form of psoriasis was significantly associated with long duration of disease (84%, P=0.005), with obese patients (74.3%, P=0.018), with hypertensive patients (81.3%, P=0.004), and with patients had low HDL (82.4%, P=0.001). <strong>Conclusion</strong>: Psoriatic patients in Iraq had higher prevalence of comorbidities in comparison to those who didn’t have psoriasis. Obesity, hypertension, and low s. HDL are positively correlated with severity of psoriasis. Psoriasis is considered as an associated risk factor that may cause depression.</p> <p><strong><em> </em></strong></p> <p><strong><em>Keyword: Psoriasis, depression, metabolic syndrome, Iraq</em></strong></p> <p><strong><em> </em></strong></p>
Multi-antigen imaging data of skin tissue samples from cutaneous T cell lymphoma, atopic dermatitis, and psoriasis patients
<h1>Data</h1> <p>Multi-antigen imaging data for 69 skin tissue samples (21 cutaneous T cell lymphoma (CTCL), 23 atopic dermatitis (AD), and 25 pseudolymphoma (PSO)), obtained from 27 patients (8 CTCL, 7 AD, 12 PSO) treated at the University Hospital Erlangen. Each sample contains at least 36 protein channels, each of resolution 512 X 512 pixels. The data were generated using multi-epitope ligand cartography (MELC) (https://doi.org/10.1038/nbt1250, https://doi.org/10.1007/3-540-36459-5_8).</p> <h1>Metadata</h1> <p>For each sample, we information on sex, age, and condition of the corresponding patient. Samples and patients are numbered as S01 through S69 and P01 through P27, respectively.</p> <h1>Structure of the repository</h1> <ul> <li>The file <strong>metadata.csv</strong> contains the metadata.</li> <li>The archive <strong>data.zip</strong> contains one directory for each sample, named with the sample numbers S01 through S69.</li> <li>The directories for the individual samples contain images named<strong> <marker>-<flourescent protein>.tif</strong>, where <marker> is the name of the quantified protein marker and <flourescent protein> is the name of the flourescent protein that was used for image acquisition.</li> </ul> <p> </p> <p> </p>
Identification of novel biomarkers related to pathogenesis and treatment of psoriasis
<p><span> Table S1.txt</span></p> <p><span>Differentially</span> <span>expressed genes</span><span> in the NL/LS cohort.</span></p> <p><span> </span><span> Table S2.txt</span></p> <p><span>Differentially</span> <span>expressed genes</span><span> in the pre/post treatment cohort.</span></p> <p><span> </span><span> Figure S1.pdf</span></p> <p><span>The heat map of differentially expressed genes.</span></p> <p><span>A: The heat map of the 50 most differentially expressed genes in NL/LS cohort.</span></p> <p><span>B: The heat map of the 50 most differentially expressed genes in pre/post treatment cohort.</span></p> <p><span> </span><span> </span><span>Figure S2.pdf</span></p> <p><span>Cluster outlier detection of NL/LS cohort.</span></p> <p><span>Figure S3.pdf</span></p> <p><span>Cluster outlier detection of pre/post treatment cohort.</span></p> <p><span> </span><span>Table S3.txt</span></p> <p><span>The results of GO enrichment analysis in </span><span>NL/LS cohort.</span></p> <p><span> </span><span>Figure S4</span><span>.pdf</span></p> <p><span>Chord diagram</span><span>: Go analysis of the key module in NL/LS cohort (Biological process).</span></p> <p><span> </span><span>Figure S5.pdf</span></p> <p><span>Chord diagram</span><span>: Go analysis of the key module in NL/LS cohort (Cellular component).</span></p> <p><span> </span><span>Figure S6.pdf</span></p> <p><span>Chord diagram</span><span>: Go analysis of the key module in NL/LS cohort (Molecular function).</span></p> <p><span> </span><span>Table S4.txt</span></p> <p><span>The results of KEGG enrichment analysis in </span><span>NL/LS cohort.</span></p> <p><span> </span><span>Table S5.txt</span></p> <p><span>The results of GO enrichment analysis in </span><span>pre/post treatment cohort.</span></p> <p><span> </span><span> Figure S7.pdf</span></p> <p><span>Chord diagram</span><span>: Go analysis of the key module in pre/post treatment cohort (Biological process).</span></p> <p><span> </span><span> Figure S8.pdf</span></p> <p><span>Chord diagram</span><span>: Go analysis of the key module in pre/post treatment cohort (Cellular component).</span></p> <p><span> </span><span> Figure S9.pdf</span></p> <p><span>Chord diagram</span><span>: Go analysis of the key module in pre/post treatment cohort (Molecular function).</span></p> <p><span> </span><span> Table S6.txt</span></p> <p><span>The results of KEGG enrichment analysis </span><span>in pre/post treatment cohort.</span></p> <p><span> Figure S10.pdf</span></p> <p><span>LASSO model</span></p> <p><span>A: </span><span>LASSO model of NL/LS cohort.</span></p> <p><span>B: LASSO model of </span><span>pre/post treatment cohort.</span></p>
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
ClinicalTrials.gov study NCT00778700. IPD Sharing: YES. Countries: 1. Publications: 0.
Peds Metabolic Syndrome in Psoriasis
ClinicalTrials.gov study NCT00930592. IPD Sharing: NO. Countries: 1. Publications: 10.
Plaque Psoriasis Efficacy and Safety With Secukinumab
ClinicalTrials.gov study NCT02409667. IPD Sharing: UNDECIDED. Countries: 24. Publications: 0.
Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
ClinicalTrials.gov study NCT05488990. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
ClinicalTrials.gov study NCT03757013. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ASIS for Enbrel in Plaque Psoriasis
ClinicalTrials.gov study NCT02112097. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, Wit
ClinicalTrials.gov study NCT05758402. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
ClinicalTrials.gov study NCT06143371. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test
ClinicalTrials.gov study NCT00578370. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.